|
1.
|
Carbone M, Kratzke RA and Testa JR: The
pathogenesis of mesothelioma. Semin Oncol. 29:2–17. 2002.
View Article : Google Scholar
|
|
2.
|
Nowak AK, Lake RA, Kindler HL and Robinson
BW: New approaches for mesothelioma: biologics, vaccines, gene
therapy, and other novel agents. Semin Oncol. 29:82–96. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ryan CW, Herndon J and Vogelzang NJ: A
review of chemotherapy trials for malignant mesothelioma. Chest.
113:S66–S73. 1998. View Article : Google Scholar
|
|
4.
|
Van Haarst JM, Baas P, Manegold CH, et al:
Multicentre phase II study of gemcitabine and cisplatin in
malignant pleural mesothelioma. Br J Cancer. 86:342–345.
2002.PubMed/NCBI
|
|
5.
|
Vinken M, Vanhaecke T, Papeleu P, et al:
Connexins and their channels in cell growth and cell death. Cell
Signal. 18:592–600. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Laird DW: Life cycle of connexins in
health and disease. Biochem J. 394:527–543. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Mesni M, Krutovskikh V, Piccoli C, et al:
Negative growth control of HeLa cells by connexin genes: connexin
species specificity. Cancer Res. 55:629–639. 1995.PubMed/NCBI
|
|
8.
|
Sato H, Iwata H, Takano Y, Yamada R,
Okuzawa H, Nagashima Y, Yamaura K, Ueno K and Yano T: Enhanced
effect of connexin 43 on cisplatin-induced cytotoxicity in
mesothelioma cells. J Pharm Sci. 110:466–475. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kennedy AR: The Bowman-Birk inhibitor from
soybeans as an anticarcinogenic agent. Am J Clin Nutri.
68:S1406–S1412. 1998.PubMed/NCBI
|
|
10.
|
Armstrong WB, Kennedy AR, Wan XS, et al:
Single-dose administration of Bowman-Birk inhibitor concentrate in
patients with oral leukoplakia. Cancer Epid Biomark Prev. 9:43–47.
2000.PubMed/NCBI
|
|
11.
|
Billings PC, Newberne PM and Kennedy AR:
Protease inhibitor suppression of colon and anal gland
carcinogenesis induced by dimethylhydrazine. Carcinogenesis.
11:1083–1086. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kennedy AR: Prevention of carcinogenesis
by protease inhibitors. Cancer Res. 54:S1999–S2005. 1994.PubMed/NCBI
|
|
13.
|
Suzuki K, Yano T, Sadzuka Y, Sugiyama T,
Seki T and Asano R: Restoration of connexin 43 by Bowman-Birk
protease inhibitor in M5076-bearing mice. Oncol Rep. 13:1247–1250.
2005.PubMed/NCBI
|
|
14.
|
Saito T, Sato H, Virgona N, Hagiwara H,
Kashiwagi K, Suzuki K, Asano R and Yano T: Negative growth control
of osteosarcoma cells by Bowman-Birk protease inhibitor from
soybean; involvement of connexin 43. Cancer Lett. 253:249–257.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Nishimura M, Saito T, Yamasaki H and Kudo
R: Suppression of gap junctional intercellular communication via 5′
CpG island methylation in promoter region of E-cadherin gene in
endometrial cancer cells. Carcinogenesis. 24:1615–1623. 2003.
|
|
16.
|
Nam S, Smith DM and Dou QP: Ester
bond-containing tea polyphenols potently inhibit proteasome
activity in vitro and in vivo. J Biol Chem. 276:13322–13330. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Tang M, Asamoto M, Ogawa K, et al:
Induction of apoptosis in the LNCaP human prostate carcinoma cell
line and prostate adenocarcinomas of SV40T antigen transgenic rats
by the Bowman-Birk inhibitor. Pathol Int. 59:790–796. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Sato H, Senba H, Virgona N, Fukumoto K,
Ishida T, Hagiwara H, Negishi E, Ueno K, Yamasaki H and Yano T:
Connexin 32 potentiates vinblastine-induced cytotoxicity in renal
cell carcinoma cells. Mol Carcinog. 46:215–224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Krutovskikh VA, Piccoli C and Yamasaki H:
Gap junction intercellular communication propagates cell death in
cancerous cells. Oncogene. 21:1989–1999. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Duflot-Dancer A, Mesnil M and Yamasaki H:
Dominant-negative abrogation of connexin-mediated cell growth
control by mutant connexin genes. Oncogene. 15:2151–2158. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Fujimoto E, Sato H, Shirai S, Nagashima Y,
Fukumoto K, Hagiwara H, Negishi E, Ueno K, Omori Y, Yamasaki H,
Hagiwara K and Yano T: Connexin32 as a tumor-suppressor gene in a
metastatic renal cell carcinoma cell line. Oncogene. 24:3684–3690.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Benati D and Baldari CT: SRC family
kinases as potential therapeutic targets for malignancies and
immunological disorders. Curr Med Chem. 15:1154–1165. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Tsao AS, He D, Saigal B, et al: Inhibition
of c-Src expression and activation in malignant pleural
mesothelioma tissues leads to apoptosis, cell cycle arrest, and
decreased migration and invasion. Mol Cancer Ther. 6:1962–1972.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Pahujaa M, Anikin M and Goldberg GS:
Phosphorylation of connexin43 induced by Src: regulation of gap
junctional communication between transformed cells. Exp Cell Res.
313:4083–4090. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Kim R, Emi M, Tanabe K, et al: Therapeutic
potential of antisense Bcl-2 as a chemosensitizer for cancer
therapy. Cancer. 101:2491–2502. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Chao DT and Korsmeyer SJ: BCL-2 family:
regulators of cell death. Ann Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar
|
|
27.
|
Hockenbery DM: Targeting mitochondria for
cancer therapy. Environ Mol Mutagenesis. 51:476–489. 2010.
View Article : Google Scholar : PubMed/NCBI
|
